Home › Compare › LNCLF vs ABBV
LNCLF yields 487.80% · ABBV yields 3.06%● Live data
📍 LNCLF pulled ahead of the other in Year 1
Combined, LNCLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LNCLF + ABBV for your $10,000?
Lincoln Gold Mining Inc. engages in the exploration and development of precious metals in the United States and Canada. The company explores for gold, copper, nickel, and cobalt deposits. It holds interests in the Pine Grove gold property with mining leases on the Wilson and Wheeler mines, and 243 unpatented claims located in the Pine Grove Hills, Lyon County, Nevada. The company also holds claims in the pre-development stage Oro Cruz gold property that consists of 151 lode claims covering an area of approximately 3,000 acres located in Imperial County, California. In addition, it has an option to acquire 100% interest in the Shawinigan property consists of 82 contiguous mineral claims covering an area of 48.4 square kilometers located in northeast of Montreal, Canada. The company was formerly known as Lincoln Mining Corporation and changed its name to Lincoln Gold Mining Inc. in September 2019. Lincoln Gold Mining Inc. is headquartered in Vancouver, Canada.
Full LNCLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.